MX2022008392A - Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. - Google Patents
Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.Info
- Publication number
- MX2022008392A MX2022008392A MX2022008392A MX2022008392A MX2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- phenylcyclohexyl
- piperidine
- oxy
- carboxylate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959514P | 2020-01-10 | 2020-01-10 | |
| PCT/US2021/012447 WO2021142083A1 (en) | 2020-01-10 | 2021-01-07 | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008392A true MX2022008392A (es) | 2022-08-08 |
Family
ID=74418549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008392A MX2022008392A (es) | 2020-01-10 | 2021-01-07 | Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12594269B2 (enExample) |
| EP (1) | EP4087534A1 (enExample) |
| JP (1) | JP7728264B2 (enExample) |
| KR (1) | KR20220127245A (enExample) |
| CN (1) | CN115226390B (enExample) |
| AU (1) | AU2021205892B2 (enExample) |
| BR (1) | BR112022013547A2 (enExample) |
| CA (1) | CA3167050A1 (enExample) |
| MX (1) | MX2022008392A (enExample) |
| WO (1) | WO2021142083A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020394444B2 (en) | 2019-11-25 | 2025-05-29 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CN119968355A (zh) | 2022-10-07 | 2025-05-09 | 橘生药品工业株式会社 | 环戊烷化合物 |
| KR20250085056A (ko) | 2023-12-05 | 2025-06-12 | 안희태 | 국궁 과녁에서 영역 구분 센서의 구성 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1317270A1 (en) * | 2000-09-08 | 2003-06-11 | Pharmacia Italia S.p.A. | Exemestane for the treatment of oestrogen-dependent cancers |
| EP2968341A4 (en) | 2013-03-14 | 2016-11-23 | Pharmacyclics Llc | COMBINATIONS OF BURTON TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS |
| EP4438041A3 (en) | 2016-02-04 | 2025-01-01 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
| JP6764017B2 (ja) | 2016-08-04 | 2020-09-30 | ギリアード サイエンシーズ， インコーポレイテッド | がんの処置での使用のためのコビシスタット |
| KR20220062361A (ko) | 2019-09-13 | 2022-05-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도 |
| US20220339143A1 (en) | 2019-09-13 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
-
2021
- 2021-01-07 WO PCT/US2021/012447 patent/WO2021142083A1/en not_active Ceased
- 2021-01-07 US US17/791,302 patent/US12594269B2/en active Active
- 2021-01-07 EP EP21702564.2A patent/EP4087534A1/en active Pending
- 2021-01-07 JP JP2022542294A patent/JP7728264B2/ja active Active
- 2021-01-07 BR BR112022013547A patent/BR112022013547A2/pt unknown
- 2021-01-07 KR KR1020227023475A patent/KR20220127245A/ko active Pending
- 2021-01-07 CA CA3167050A patent/CA3167050A1/en active Pending
- 2021-01-07 MX MX2022008392A patent/MX2022008392A/es unknown
- 2021-01-07 CN CN202180017795.5A patent/CN115226390B/zh active Active
- 2021-01-07 AU AU2021205892A patent/AU2021205892B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3167050A1 (en) | 2021-07-15 |
| BR112022013547A2 (pt) | 2022-09-06 |
| AU2021205892A1 (en) | 2022-08-18 |
| CN115226390A (zh) | 2022-10-21 |
| US12594269B2 (en) | 2026-04-07 |
| KR20220127245A (ko) | 2022-09-19 |
| EP4087534A1 (en) | 2022-11-16 |
| WO2021142083A1 (en) | 2021-07-15 |
| JP7728264B2 (ja) | 2025-08-22 |
| AU2021205892B2 (en) | 2026-04-23 |
| JP2023510332A (ja) | 2023-03-13 |
| CN115226390B (zh) | 2026-03-20 |
| US20230029486A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3174139A1 (en) | Rna-editing compositions and methods of use | |
| EP4628167A3 (en) | Substituted macrocyclic compounds and related methods of treatment | |
| EP4306116A3 (en) | Methods and compositions for editing rnas | |
| EP4015654A4 (en) | COMPOSITION, KIT AND METHOD FOR CORONAVIRUS DETECTION AND TYPING | |
| PH12021552613A1 (en) | METHODS AND COMPOSITIONS FOR EDITING RNAs | |
| BR112022003970A2 (pt) | Métodos e composições para integração genômica | |
| PH12022553269A1 (en) | Composition, kit and method for detecting sars-cov-2 and use thereof | |
| IL199403A0 (en) | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer | |
| WO2008027932A3 (en) | Cytochrome p450 oxidase inhibitors and uses thereof | |
| TN2009000249A1 (en) | Mapk/erk kinase inhibitors | |
| WO2021048821A8 (en) | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness | |
| BR112022013547A2 (pt) | Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição | |
| CR20230100A (es) | Compuestos fosfolípidos y usos de los mismos | |
| ZA202402178B (en) | 3clpro protease inhibitor | |
| MX2022012942A (es) | Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina. | |
| MX2022001933A (es) | Inhibidores de enzimas. | |
| TW200834248A (en) | Liquid-immersion exposure method and liquid-immersion exposure apparatus | |
| CO2019001046A2 (es) | Mancha blanca | |
| TWI347627B (en) | Work piece transfer appratus and method for an ion beam implanter | |
| WO2022079128A3 (en) | Compositions and methods for masking off-notes in consumables | |
| MX2026002406A (es) | Degradadores del transductor de señales y activador de la transcripción 6 (stat6) y usos de los mismos | |
| TW200610036A (en) | Improved magnet for scanning ion beams | |
| SG126050A1 (en) | Laser beam processing machine | |
| HRP20050557A2 (en) | Method for improving the pharmacokinetics of a nnrti | |
| MX2022016546A (es) | Agente anticoccidio y metodo para su uso. |